Company Profile

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Employees

Sector

Biotechnology & Medical Research

More about the company

02/11/18	Bayer : CEO backs group's diversified structure	RE
23/10/18	AstraZeneca : digs deeper into cancer with Innate stake	RE
18/10/18	European shares edge up as earnings flurry quells Fed angst	RE
18/10/18	Endocyte : Novartis pushes deeper into nuclear medicine with $2.1 billion deal	RE
18/10/18	Endocyte : Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate	RE

20/12/18	Endocyte Stockholders Approve Merger Agreement with Novartis AG	GL
17/11/18	Monteverde & Associates PC : Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York	PR
08/11/18	Endocyte Provides Third Quarter 2018 Financial Results and Operational Update	GL
02/11/18	Monteverde & Associates PC Announces An Investigation Of Endocyte, Inc. - ECYT	PR
18/10/18	Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion	GL

14/11/18	PHARMA-L'allemand Merck abaisse sa prévision de bénéfice annuel
13/11/18	PHARMA-Bayer résiste au T3, malgré l'euro fort et la santé animale
08/11/18	PHARMA-AstraZeneca prévoit des années de croissance
06/11/18	PHARMA-Eli Lilly relève sa prévision annuelle de bénéfice
02/11/18	PHARMA-AbbVie dépasse les attentes et relève sa prévision de bénéfice

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Iontcho Vlahov PRN	Corporate Officer/Principal	-	19/07/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENDOCYTE, INC.	-.--%	+0.54%	-	-	0
ARGENX SE	+0.21%	-6.28%	+56.18%	+127.90%	54.49B
WUXI APPTEC CO., LTD.	+6.05%	+7.79%	+62.23%	+88.46%	55.93B
INSMED INCORPORATED	+0.89%	-2.42%	+8.07%	+434.51%	23.87B
BIONTECH SE	+0.37%	-4.13%	-18.56%	-16.48%	22.86B
WUXI BIOLOGICS (CAYMAN) INC.	+4.19%	+11.44%	+45.57%	-2.72%	20B
GENMAB A/S	-2.29%	-1.92%	+35.57%	-29.14%	17.48B
PHARMAESSENTIA CORPORATION	-4.00%	-10.96%	+181.91%	+328.17%	15.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.59%	+11.60%	+49.61%	+718.67%	15.19B
EXELIXIS, INC.	-0.48%	-2.30%	+22.36%	+187.62%	14.02B
Average	+1.22%	-1.83%	+49.21%	+204.11%	26.58B
Weighted average by Cap.	+1.94%	-0.49%	+48.95%	+166.98%

Endocyte, Inc. Stock

Stocks

US29269A1025

Biotechnology & Medical Research

Latest news : Endocyte, Inc.

Press Releases: Endocyte, Inc.

News in other languages: Endocyte, Inc.

Managers and Directors: Endocyte, Inc.

Bio Therapeutic Drugs

Company Profile